Enhancing Outcomes of Radiation Therapy for Prostate Cancer
Abstract
Prostate cancer (PCa) remains the most common malignancy and the second leading cause of cancer-related death for men in the United States. Every year tens of thousands of men in the US undergo treatment with of radiation therapy as a primary treatment for localized PCa. While results are often excellent, approximately one third will develop biochemical recurrence in 10 years and up to a third of men with biochemical recurrence will die of their disease, particularly men with higher stage and higher grade disease. In addition, thousands of men receive adjuvant radiation therapy following radical prostatectomy to try and prevent recurrence or for palliation of metastatic disease. Thus, improving outcomes of radiation therapy will have an immediate impact in the lives of men with PCa. In this proposal, we will determine the extent to which inhibition of two key prosurvival signaling pathways (RET and FGF receptors), alone and/or in combination, can enhance the effectiveness of radiation therapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2021
- Accession Number
- AD1156752
Entities
People
- Michael M. Ittmann
Organizations
- Baylor College of Medicine